Inozyme Pharma, Inc.
DelistedCIK 1693011fmd_1ZZ2T6401H7NRZM0JKFN1DK9R2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2025, 25 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Research and development | 16 | 46 | 38 | 48 | 55 | 83 |
| Total operating expenses | 21 | 57 | 57 | 69 | 76 | 104 |
| Operating income | (21) | (57) | (57) | (69) | (76) | (104) |
| Interest expense | – | – | – | 0 | 3 | 6 |
| Interest and investment income | 1 | 0 | 0 | 2 | 8 | 8 |
| Other non-operating income (expense) | 1 | 1 | 0 | 2 | 4 | 2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (20) | (56) | (57) | (67) | (71) | (102) |